The buy side says: “He takes a long-term view but doesn’t overlook short-term opportunities.”
Timothy Anderson, 42, repeats in first place, thanks to his “insight into the patent cliff that is not only profound but also profoundly actionable. He’s the best at keeping us up-to-speed on expiries and pipeline replenishment,” insists one buy-side counterpart. Another cites his “work on putting U.S. big pharma in a global context.” Back in January the Sanford C. Bernstein & Co. analyst, who works out of San Francisco, flagged the probability of off-patent competition for Sanofi-Aventis’ blood-clot medication Lovenox, which had global sales of $3.9 billion last year. A generic formulation received clearance from the U.S. Food and Drug Administration in July, and by late August the French pharmaceuticals giant’s American depositary receipts were down 20.8 percent for the year, from $36.13 to $28.61, and trailed the sector by 11.8 percentage points. “Margins! Anyone can poll doctors and come up with potential revenue numbers, but he is a master at figuring out how profitable these drugs are,” says one fan.
